HC Wainwright Issues Positive Estimate for Genelux Earnings

Genelux Corporation (NASDAQ:GNLX) – Analysts at HC Wainwright raised their FY2025 earnings estimates for Genelux in a report released on Thursday, November 6th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.85) per share for the year, up from their prior forecast of ($0.97). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q4 2025 earnings at ($0.23) EPS, FY2026 earnings at ($1.18) EPS, FY2027 earnings at ($0.94) EPS, FY2028 earnings at $0.42 EPS and FY2029 earnings at $1.61 EPS.

Other equities analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a report on Wednesday, October 8th. Lake Street Capital initiated coverage on shares of Genelux in a report on Tuesday, October 21st. They issued a “buy” rating and a $16.00 price objective for the company. Maxim Group set a $20.00 price objective on shares of Genelux in a research report on Tuesday, October 21st. Finally, Loop Capital set a $16.00 target price on Genelux in a research report on Tuesday, October 21st. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Genelux presently has an average rating of “Moderate Buy” and an average price target of $21.00.

Genelux Trading Up 2.3%

Shares of GNLX stock opened at $5.42 on Monday. Genelux has a twelve month low of $1.99 and a twelve month high of $8.53. The stock has a market cap of $206.23 million, a P/E ratio of -6.16 and a beta of -0.10. The stock has a 50 day moving average of $5.18 and a 200 day moving average of $3.78.

Genelux (NASDAQ:GNLX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02.

Institutional Investors Weigh In On Genelux

Several large investors have recently bought and sold shares of GNLX. Goldman Sachs Group Inc. acquired a new stake in shares of Genelux in the first quarter worth approximately $239,000. Alyeska Investment Group L.P. purchased a new position in Genelux in the 1st quarter valued at $770,000. Woodward Diversified Capital LLC boosted its stake in Genelux by 21.7% during the 2nd quarter. Woodward Diversified Capital LLC now owns 1,778,286 shares of the company’s stock worth $5,104,000 after purchasing an additional 317,173 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Genelux during the 1st quarter worth $215,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Genelux during the first quarter worth $68,000. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.